User:Mr. Ibrahem/Lacosamide
Clinical data | |
---|---|
Trade names | Vimpat |
Other names | (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609028 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Anticonvulsant[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High |
Elimination half-life | 13 hours |
Excretion | Kidney |
Identifiers | |
| |
Chemical and physical data | |
Formula | C13H18N2O3 |
Molar mass | 250.298 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Lacosamide, sold under the brand name Vimpat among others, is a medication used to treat epilepsy and diabetic neuropathic pain.[1][2] It is taken by mouth or injection into a vein.[1] It may be taken by itself or with other medications.[1]
Common side effects include dizziness, headache, nausea, tiredness, tremor, and diarrhea.[1] Other side effects may include syncope, arrhythmias including atrial fibrillation, poor coordination, and suicide.[1] There are concerns that use in pregnancy may harm the baby.[1] How it works is not entirely unclear, but it is beleived to affect sodium channels in the brain.[2]
Lacosamide was approved for medical use in the United States and Europe in 2008.[1][2] In the United States a dose of 100 mg twice per day costs about 1,000 USD per month as of 2021.[3] In Canada this amount costs about 200 CAD.[4] In the United Kingdom this amount costs the NHS about £95.[5]
References[edit]
- ^ a b c d e f g h i j "Lacosamide Monograph for Professionals". Drugs.com. Archived from the original on 10 August 2020. Retrieved 20 November 2021.
- ^ a b c d e "Vimpat". Archived from the original on 1 August 2021. Retrieved 20 November 2021.
- ^ "Vimpat Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 20 January 2021. Retrieved 20 November 2021.
- ^ "Lacosamide" (PDF). CADTH. 2011. Archived (PDF) from the original on 20 October 2020. Retrieved 20 November 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 334. ISBN 978-0857114105.